Pyrazolines as par-1 antagonists for treatment of...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/4155 (2006.01) A61P 9/00 (2006.01) C07D 401/04 (2006.01) C07D 401/14 (2006.01) C07D 403/04 (2006.01) C07D 403/14 (2006.01) C07D 405/14 (2006.01) C07D 409/14 (2006.01) C07D 413/04 (2006.01) C07D 413/14 (2006.01) C07D 417/04 (2006.01) C07D 417/14 (2006.01)

Patent

CA 2532316

The invention relates to pyrazolines of formula (I), where E = methylene, NH, O or S and R2 = a group of formula (II), methods for the production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular, cardiovascular diseases, such as thromboembolitic diseases.

L'invention concerne des pyrazolines de formule (I) dans laquelle E désigne méthylène, NH désigne un atome d'oxygène ou un atome de soufre, R?2¿ désigne un groupe de formule (II). L'invention concerne également des procédé permettant de produire lesdites pyrazolines et leur utilisation pour préparer des médicaments utilisés dans le traitement et/ou la prophylaxie de pathologies, notamment de maladies cardio-vasculaires, comme par ex. des maladies thromboemboliques.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Pyrazolines as par-1 antagonists for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrazolines as par-1 antagonists for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolines as par-1 antagonists for treatment of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1887711

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.